Total Payments
$597.55
2023 Payments
$46.74
Companies
10
Transactions
36
Medicare Patients
3,445
Medicare Billing
$296,049
Payment Breakdown by Category
Food & Beverage$597.55 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $597.55 | 36 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $203.78 | 17 | $0 (2020) |
| GlaxoSmithKline, LLC. | $175.90 | 5 | $0 (2022) |
| Amgen Inc. | $73.38 | 5 | $0 (2021) |
| AbbVie Inc. | $29.92 | 2 | $0 (2021) |
| Bayer Healthcare Pharmaceuticals Inc. | $29.66 | 1 | $0 (2023) |
| PFIZER INC. | $27.54 | 2 | $0 (2021) |
| HeartFlow, Inc. | $17.08 | 1 | $0 (2023) |
| Eisai Inc. | $14.88 | 1 | $0 (2021) |
| Amryt Pharma Holdings Ltd | $13.45 | 1 | $0 (2021) |
| Ironwood Pharmaceuticals, Inc | $11.96 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $46.74 | 2 | Bayer Healthcare Pharmaceuticals Inc. ($29.66) |
| 2022 | $19.04 | 1 | GlaxoSmithKline, LLC. ($19.04) |
| 2021 | $101.74 | 7 | AbbVie Inc. ($29.92) |
| 2020 | $60.11 | 4 | Allergan, Inc. ($28.11) |
| 2019 | $35.43 | 3 | Allergan Inc. ($21.72) |
| 2018 | $158.81 | 4 | GlaxoSmithKline, LLC. ($130.61) |
| 2017 | $175.68 | 15 | Allergan Inc. ($125.75) |
All Payment Transactions
36 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/18/2023 | HeartFlow, Inc. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $17.08 | General |
| Category: Coronary | ||||||
| 03/08/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $29.66 | General |
| Category: Cardio-renal | ||||||
| 02/17/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: RESPIRATORY | ||||||
| 09/21/2021 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $14.88 | General |
| 09/14/2021 | Amryt Pharma Holdings Ltd | JUXTAPID (Drug) | Food and Beverage | In-kind items and services | $13.45 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/27/2021 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/01/2021 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: Bone Health | ||||||
| 03/17/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: NEUROSCIENCE | ||||||
| 03/17/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $12.27 | General |
| Category: RESPIRATORY | ||||||
| 03/04/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.32 | General |
| Category: NEUROSCIENCE | ||||||
| 10/27/2020 | Allergan, Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: NEUROSCIENCE | ||||||
| 10/21/2020 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: Bone Health | ||||||
| 08/21/2020 | Allergan, Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: NEUROSCIENCE | ||||||
| 06/16/2020 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: RESPIRATORY | ||||||
| 09/06/2019 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.92 | General |
| Category: NEUROSCIENCE | ||||||
| 09/05/2019 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $13.71 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/25/2019 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.80 | General |
| Category: NEUROSCIENCE | ||||||
| 04/10/2018 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: VACCINES | ||||||
| 03/07/2018 | GlaxoSmithKline, LLC. | FLUARIX (Biological) | Food and Beverage | In-kind items and services | $5.62 | General |
| Category: VACCINES | ||||||
| 02/28/2018 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.35 | General |
| Category: NEUROSCIENCE | ||||||
| 01/11/2018 | Allergan Inc. | NAMZARIC (Drug) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: NEUROSCIENCE | ||||||
| 12/19/2017 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: NEUROSCIENCE | ||||||
| 12/12/2017 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.84 | General |
| Category: NEUROSCIENCE | ||||||
| 12/07/2017 | Allergan Inc. | NAMZARIC (Drug) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: NEUROSCIENCE | ||||||
| 09/25/2017 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 509 | 932 | $97,928 | $48,355 |
| 2022 | 12 | 654 | 1,186 | $121,327 | $60,105 |
| 2021 | 15 | 953 | 1,749 | $174,115 | $89,453 |
| 2020 | 18 | 1,329 | 2,246 | $214,703 | $98,136 |
Total Patients
3,445
Total Services
6,113
Medicare Billing
$296,049
Procedure Codes
56
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 92 | 321 | $43,335 | $26,176 | 60.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 73 | 73 | $14,600 | $9,230 | 63.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 46 | 85 | $8,075 | $5,000 | 61.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 92 | 247 | $17,290 | $2,251 | 13.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 15 | $3,000 | $1,954 | 65.1% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 27 | 27 | $3,375 | $1,273 | 37.7% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 23 | 23 | $2,875 | $1,143 | 39.8% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 36 | 36 | $3,240 | $722.25 | 22.3% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2023 | 73 | 73 | $1,460 | $287.62 | 19.7% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 13 | 13 | $260.00 | $236.73 | 91.1% |
| 82270 | Stool analysis for blood to screen for colon tumors | Office | 2023 | 19 | 19 | $418.00 | $81.51 | 19.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 106 | 406 | $54,810 | $34,588 | 63.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 79 | 79 | $15,800 | $10,199 | 64.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 43 | 67 | $6,365 | $4,242 | 66.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 104 | 288 | $20,160 | $2,634 | 13.1% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2022 | 45 | 46 | $5,750 | $2,257 | 39.3% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2022 | 34 | 34 | $4,250 | $1,694 | 39.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 12 | $2,400 | $1,691 | 70.5% |
| 93701 | Measurement of heart blood flow and respiration | Office | 2022 | 66 | 86 | $5,590 | $1,337 | 23.9% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 40 | 40 | $3,600 | $619.70 | 17.2% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 23 | 23 | $460.00 | $419.52 | 91.2% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2022 | 82 | 84 | $1,680 | $332.84 | 19.8% |
| 82270 | Stool analysis for blood to screen for colon tumors | Office | 2022 | 21 | 21 | $462.00 | $90.41 | 19.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 109 | 448 | $60,300 | $39,906 | 66.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 94 | 94 | $18,800 | $12,397 | 65.9% |
About Dr. Michael Festino, M.D
Dr. Michael Festino, M.D is a Cardiovascular Disease healthcare provider based in Saco, Maine. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/17/2005. The National Provider Identifier (NPI) number assigned to this provider is 1124010111.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Festino, M.D has received a total of $597.55 in payments from pharmaceutical and medical device companies, with $46.74 received in 2023. These payments were reported across 36 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($597.55).
As a Medicare-enrolled provider, Festino has provided services to 3,445 Medicare beneficiaries, totaling 6,113 services with total Medicare billing of $296,049. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Saco, ME
- Active Since 08/17/2005
- Last Updated 09/22/2010
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1124010111
Products in Payments
- VRAYLAR (Drug) $165.44
- SHINGRIX (Biological) $124.99
- TRELEGY ELLIPTA (Drug) $45.29
- NAMZARIC (Drug) $39.12
- EVENITY (Biological) $35.41
- Kerendia (Drug) $29.66
- VYNDAQEL (Drug) $27.54
- Repatha (Biological) $24.19
- VIBERZI (Drug) $19.55
- FFRct (Device) $17.08
- Prolia (Biological) $13.78
- JUXTAPID (Drug) $13.45
- ZURAMPIC (Drug) $11.96
- LINZESS (Drug) $9.59
- FLUARIX (Biological) $5.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.